As multidisciplinary stakeholders consider how to reform the prescription drug pricing structure, one recent proposal is gaining traction. Drugs pushed through the accelerated approval pathway (AAP), such as Biogen’s iffy Aduhelm, could enter the market at a lower price until sufficient evidence confirms their clinical efficacy. This could soon be the case for a wide variety of therapeutic products, including oncology drugs.
Geriatrician and dementia expert James Mittelberger, MD, MPH remarks, “Imagine the disgust and discredit that will flow to the medical profession and CMS if tens of billions of dollars are spent on a treatment that is not significantly effective,” adding, “Yes, people want hope and new treatments, but we are not doing good by offering ineffective treatments for fatal conditions.” Read more here.
(Source: Kerry Dooley Young, 9/29/21)
